IGF2BP1 and breast carcinoma: Breast cancer cases with high proliferation rates exhibited elevated IGF2BP1, IGF2BP2, and IGF2BP3 expression (FC: 4.87, 2.04, and 9.27, respectively) (Fig. 1G–I), while no significant correlation was found between Ki67 expression and METTL14.